证券代码：002286 证券简称：保龄宝 公告编号：2025-032 保龄宝生物股份有限公司董事会薪酬与考核委员会 关于2025年限制性股票激励计划 首次授予激励对象名单的核查意见及公示情况说明 本公司及董事会薪酬与考核委员会全体成员保证信息披露内容的真实、准 确和完整，没有虚假记载、误导性陈述或重大遗漏 保龄宝生物股份有限公司（以下简称"公司"）于2025年4月24日召开了第六 届董事会第九次会议，审议通过了《关于 <保龄宝生物股份有限公司2025年限制> 性股票激励计划（草案）>及其摘要的议案》等议案。 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上市公司股 权激励管理办法》（以下简称"《管理办法》"）等法律、法规及规范性文件和 《保龄宝生物股份有限公司章程》（以下简称"《公司章程》"）的规定，公司 对2025年限制性股票激励计划（以下简称"本激励计划"）首次授予激励对象的 姓名和职务在公司内部进行了公示。公司董事会薪酬与考核委员会结合公示情 况对激励对象相关信息进行了核查，相关公示情况及核查意见如下： 司章程》等法律、法规和规范性文件规定的激励对象条件，符合《激励计划 （草案）》规定的激励对 ...

证券代码：002286 证券简称：保龄宝 公告编号：2025-032 保龄宝生物股份有限公司董事会薪酬与考核委员会 关于2025年限制性股票激励计划 首次授予激励对象名单的核查意见及公示情况说明 本公司及董事会薪酬与考核委员会全体成员保证信息披露内容的真实、准 确和完整，没有虚假记载、误导性陈述或重大遗漏 保龄宝生物股份有限公司（以下简称"公司"）于2025年4月24日召开了第六 届董事会第九次会议，审议通过了《关于<保龄宝生物股份有限公司2025年限制 性股票激励计划（草案）>及其摘要的议案》等议案。 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上市公司股 权激励管理办法》（以下简称"《管理办法》"）等法律、法规及规范性文件和 《保龄宝生物股份有限公司章程》（以下简称"《公司章程》"）的规定，公司 对2025年限制性股票激励计划（以下简称"本激励计划"）首次授予激励对象的 姓名和职务在公司内部进行了公示。公司董事会薪酬与考核委员会结合公示情 况对激励对象相关信息进行了核查，相关公示情况及核查意见如下： 一、公示情况及核查方式 1、公司于2025年4月25日于巨潮资讯网（www.cninfo.co ...

Market Outlook - The market for health-conscious products is expected to grow significantly due to rising income levels and changing consumer preferences towards sugar-free and nutritious options [2] - The aging population presents a substantial opportunity in the silver economy, with increasing demand for health improvement products [2] - National policies are anticipated to further boost the market for natural sweeteners and functional health foods such as prebiotics and dietary fibers [2] Revenue Projections - The company aims for a net profit of no less than 170 million RMB in 2025 as part of its stock incentive plan [6] - The company expects stable growth in its three core products: prebiotics, dietary fibers, and sugar-reducing sweeteners [4] Production Capacity - The company has initiated a project to expand its production capacity of allulose to 20,000 tons annually, with an expected total capacity of approximately 30,000 tons by 2026 [3] - The company has completed the construction of a 2,500-ton annual production line for HMOs (human milk oligosaccharides) and is currently in the trial production phase [6] Impact of Raw Material Prices - The company is closely monitoring corn prices and employing strategies to balance procurement costs and market uncertainties [3] Export and Market Expansion - The company plans to establish a sales subsidiary in the U.S. and enhance customer service to increase market share [7] - The company’s export business to the U.S. is expected to benefit from reduced tariffs, which will facilitate exports [4] Industry Trends - The overall industry is benefiting from the growing health consciousness among consumers and the aging population, which is driving demand for health-related products [11] - The company’s market share for erythritol in the EU has increased to 50%, with a significant revenue growth of approximately 123% year-on-year in Q1 2025 [5] Stock Performance and Investor Relations - The company is actively engaging in investor relations to improve market perception and stock performance, including hosting analyst meetings and enhancing information disclosure [10] - The company acknowledges that stock price is influenced by various factors, including company earnings and market conditions [12]

保龄宝生物股份有限公司 股票简称：保龄宝 股票代码：002286 公告编号：2025-031 特此公告！ 保龄宝生物股份有限公司 关于参加2025年山东辖区上市公司投资者 网上集体接待日活动的公告 为进一步加强与投资者的互动交流，保龄宝生物股份有限公司（以下简称"公 司"）将参加由山东证监局、山东上市公司协会与深圳市全景网络有限公司联合 举办的"2025年山东辖区上市公司投资者网上集体接待日活动"，现将相关事项 公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路 演APP,参与本次互动交流。活动时间为2025年5月15日（周四）15:00-16:30。 届时公司高管将在线就公司2024年度业绩、公司治理、发展战略、经营状况、 融资计划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交 流，欢迎广大投资者踊跃参与！ 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 董事会 2025 年 5 月 12 日 ...

Group 1: Key Recommendations - The report highlights the strong growth potential of Baolingbao (002286) driven by product structure optimization and benefits from anti-dumping measures, with a projected revenue of 2,581 million CNY in 2025, growing at a rate of 7.46% [6] - The company is expected to achieve a net profit of 181 million CNY in 2025, reflecting a significant growth rate of 62.89% [6] - The report suggests that the impact of trade conflicts on the company is minimal due to its low overseas revenue contribution, with 76% of revenue coming from the domestic market [6] Group 2: Industry Insights - The A-share market is anticipated to undergo a phase of "active adjustment," with a focus on structural changes in holdings and waiting for external news, particularly regarding tariff negotiations [8] - The macroeconomic outlook indicates a potential U-shaped trajectory for the economy, with slower price recovery expected in the second quarter compared to the first [10] - The bond market is expected to see opportunities for long-term bonds as the market gradually returns to fundamental trading, following recent monetary policy adjustments [12] Group 3: Company Performance - Taotao Automotive (301345) reported a remarkable 69% year-on-year growth in Q1, indicating a strong market position and potential for continued market share expansion [14] - The company is benefiting from accelerated production capacity in Southeast Asia and the U.S., along with exceeding expectations in golf cart orders [14] - The report emphasizes the importance of monitoring trade dynamics as a catalyst for future performance [14]

股票简称：保龄宝 股票代码：002286 公告编号：2025-030 保龄宝生物股份有限公司 关于公司副总经理辞职的公告 本公司及董事会全体成员保证本公告内容真实、准确和完整，没有任何虚 假记载、误导性陈述或者重大遗漏。 保龄宝生物股份有限公司（以下简称"保龄宝"或"公司"）董事会于近日 收到公司副总经理王延军先生的书面辞职报告。王延军先生因个人原因辞去公司 副总经理职务，辞职后不在公司担任任何职务。根据公司章程的有关规定，王延 军先生的辞职报告自送达公司董事会时生效。王延军先生的工作已进行妥善交接， 不会影响公司日常生产经营活动。 截至本公告披露日，王延军先生未持有公司股票,不存在应当履行而未履行 的承诺事项。王延军先生在担任公司副总经理期间，恪尽职守、勤勉尽责，董事 会对王延军先生为公司发展作出的贡献表示衷心感谢！ 特此公告。 保龄宝生物股份有限公司董事会 2025 年 5 月 12 日 ...

Investment Rating - The report gives a "Buy" rating for the company, marking the first coverage of the stock [2]. Core Insights - The introduction of professional managers has aided the company's reform, with product structure optimization driving profit improvement. The company has a rich product matrix in functional sugars and nutritional supplements, and has successfully adjusted its operational strategies during industry downturns, leading to a significant rebound in profit and gross margin improvement [1]. - The company stands to benefit from anti-dumping measures on erythritol and is positioned to capture the growing domestic market for allulose. With a production capacity of 30,000 tons per year, the company is expected to see volume and price increases in the European market due to its favorable anti-dumping tax rate [1]. - In 2024, all major segments achieved growth in both sales volume and gross margin, with a net profit of 111 million yuan, a year-on-year increase of 106%. The company has set ambitious performance targets for its stock incentive plan, reflecting confidence in future growth [1]. Summary by Sections Company Overview - Founded in 1997, the company is a leading player in the functional sugar industry in China, focusing on the research and production of biological (multi)sugars. It has established strategic partnerships with global giants like Coca-Cola and Yili, and has a comprehensive product system covering various functional sugars [18][21]. Management and Strategy - The company has undergone significant management restructuring, bringing in experienced professionals to enhance strategic planning and operational efficiency. The management team now combines international experience with local insights, which is expected to strengthen the company's competitive position in the functional sugar sector [24][25]. Financial Performance - The company forecasts net profits of 181 million, 216 million, and 260 million yuan for 2025, 2026, and 2027, respectively, with corresponding PE ratios of 20.07, 16.82, and 13.99 times. This indicates a strong growth trajectory compared to industry averages [2][12]. Product Segments - The company has diversified its product offerings, including prebiotics, dietary fibers, and sugar substitutes, which are experiencing rapid growth in demand. The market for these products is expected to expand significantly, driven by increasing consumer health awareness [1][7][23]. Market Outlook - The report highlights the potential for growth in the allulose market and the stability of the erythritol market, suggesting that the company is well-positioned to capitalize on these trends. The anticipated approval of allulose in China is expected to open up new market opportunities [1][10].

Group 1 - The company has introduced professional managers to assist in reform and optimize product structure, leading to improved profitability. The company, established in 1997, has a diverse product matrix in functional sugars and nutritional supplements, consisting of five layers: starch sugars, reduced-sugar sweeteners, prebiotics, dietary fibers, and special functional food ingredients. After the peak and subsequent decline of erythritol in 2019, the company adjusted its operational strategies and product structure during the industry downturn, resulting in a significant rebound in profits and gross margin improvement last year [1] - Erythritol is benefiting from anti-dumping measures, and there is a focus on the domestic market potential for allulose. Following the surge in popularity of erythritol in 2021, prices have stabilized at a low point due to new production capacities. The company has an annual capacity of 30,000 tons and is the domestic enterprise with the lowest anti-dumping tax rate in the EU, which is expected to lead to a rise in both volume and price in the European market. The optimal marginal pricing for the company in Europe is estimated at 15,800 yuan per ton, higher than the domestic price of 6,500 yuan per ton. Additionally, the U.S. has initiated a "double anti" investigation against Chinese erythritol, with preliminary anti-dumping tax rates set at 260%-450%. The company is not a mandatory respondent, and attention should be paid to the market changes in the U.S. following the May tax rate announcement. Allulose, as a new star in the sugar substitute market, has significant growth potential, with domestic approval expected in March [1][2] Group 2 - In 2024, all major segments of the company achieved growth in both sales and gross margin, with stock incentives reflecting confidence in future development. The company reported a net profit attributable to shareholders of 111 million yuan in 2024, a year-on-year increase of 106%. The growth was driven by increased sales and gross margins across key revenue segments, with sales volumes for prebiotics, dietary fibers, reduced-sugar sweeteners, starch sugars, and others reaching 357,000 tons, 214,000 tons, 500,000 tons, and 2,426,000 tons, respectively, representing year-on-year growth of 23.74%, 14.39%, 41.66%, and 2.29%. Gross margins for these segments were 24.60%, 18.12%, 9.09%, and 12.22%, with year-on-year increases of 5.26 percentage points, 5.48 percentage points, 7.83 percentage points, and 2.17 percentage points. The company announced stock incentives for 2024, with performance targets for 2025-2027 set at 170 million yuan, 212 million yuan, and 265 million yuan, corresponding to growth rates of 53%, 25%, and 25%, demonstrating confidence in future development [2] Group 3 - Profit forecasts and valuations indicate that the company is expected to achieve net profits attributable to shareholders of 181 million yuan, 216 million yuan, and 260 million yuan from 2025 to 2027, with corresponding PE valuations of 20.07, 16.82, and 13.99 times. The initial coverage has been initiated with a "buy" rating [3]

证券代码：002286 证券简称：保龄宝 公告编号：2025-029 保龄宝生物股份有限公司 关于举行 2024 年年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 保龄宝生物股份有限公司(以下简称"公司")已于 2025 年 4 月 25 日在巨潮 资讯网(www.cninfo.com.cn)上披露了《2024 年年度报告》。为使投资者更深入、 全面地了解公司 2024 年年度报告的内容，公司定于 2025 年 5 月 12 日（星期一） 15:00-16:00 在"价值在线"（www.ir-online.cn）举办保龄宝生物股份有限公 司 2024 年年度业绩说明会，与投资者进行沟通和交流，广泛听取投资者的意见 和建议。 一、说明会召开的时间、地点和方式 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 会议召开时间：2025 年 5 月 12 日（星期一）15:00-16:00 二、参加人员 为充分尊重投资者、提升交流的针对性，现就公司 2024 年年度业绩说明会 提前向投资者公开征集问题，广泛听 ...

A股农产品加工板块震荡走强，保龄宝封板涨停，*ST佳沃涨超8%，欧福蛋业涨近6%，邦基科技、*ST 中基等均涨超3%。 ...